New agreement aims to enhance global access to immunoassay products.
- QuidelOrtho has entered a strategic supply agreement.
- The agreement aims to enhance its immunoassay offerings.
- This move will expand global access to essential health products.
QuidelOrtho has announced a strategic supply agreement designed to broaden its global immunoassay portfolio. This initiative is part of the company's ongoing commitment to enhance health diagnostics and support healthcare professionals worldwide. The expanded range of immunoassays is expected to improve access to critical diagnostic testing.
The agreement focuses on increasing the availability of QuidelOrtho's immunoassay products in various international markets. With this collaboration, the company aims to meet the growing demand for precise and reliable diagnostic tools, bolstering its position in the healthcare landscape. The partnership is anticipated to provide health professionals with vital resources to aid in patient care.
While details regarding specific products included in the agreement have not been disclosed, the development underscores QuidelOrtho's commitment to innovation and improving healthcare outcomes globally. The expansion of its global immunoassay portfolio is aligned with the increasing need for timely and accurate diagnostic testing across diverse populations.
